MedPath

Effect of Oxytocin Nasal Sprays on Social Behavior in Social Anxiety Disorder

Phase 1
Completed
Conditions
Social Anxiety Disorder
Interventions
Drug: Placebo
Registration Number
NCT01856530
Lead Sponsor
Stefan G. Hofmann
Brief Summary

The purpose of this study is to learn more about how the hormone, oxytocin, impacts social behavior in terms of cooperation with others, attention processing, and reward processing, among patients with social anxiety disorder. Based on available research, the investigators predict that in patients with social anxiety disorder, oxytocin will improve social cooperation during an online ball-tossing game called Cyberball, reduce attention toward socially threatening cues during a dot-probe task, and lead to greater willingness to work for monetary rewards for others rather than themselves during an effort expenditure task.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
60
Inclusion Criteria
  • Males > 18 years of age with a primary (or co-principal) psychiatric diagnosis of social anxiety disorder (SAD), as defined by Diagnostic and Statistical Manual-IV (DSM-IV) criteria;
  • Current Liebowitz Social Anxiety Scale (LSAS) score > 60, which is a clinical threshold for SAD symptoms;
  • Comorbid present DSM-IV Major Depression, Dysthymia, Specific Phobia, or any of the other anxiety disorders as diagnosed by DSM-IV criteria will be permitted as long as SAD is primary (the disorder that is most distressing to the patient). Inclusion of patients with comorbidity will permit accrual of a more clinically relevant patient population;
  • Willingness to participate in and comply with the study procedures as indicated by signing the informed consent form.
Exclusion Criteria
  • Subjects with a serious medical illness for which hospitalization may be likely within the next three months;
  • Subjects with a current diagnosis of schizophrenia, psychotic disorders, bipolar disorder, mental disorder due to a medical condition or substance, substance abuse or dependence, as diagnosed by DSM-IV criteria;
  • Concurrent use of other psychotropic medications is excluded, except for antidepressants that have been taken at a stable dose for at least 2 weeks;
  • Active suicidal or homicidal ideation or suicide attempts within the past six months requiring hospitalization;
  • Subjects with significant nasal pathology (atrophic rhinitis, recurrent nose bleeds, or history of hypophysectomy);
  • Smokers who smoke more than 15 cigarettes per day;
  • Those who smoke cigarettes or have caffeine or alcohol within 24 hours of the study visit.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboMatched placebo nasal spray
OxytocinOxytocinLiquid intranasal oxytocin, 24 IU, administered once
Primary Outcome Measures
NameTimeMethod
Social CooperationDay 1 (first day oxytocin or placebo was administered)

The outcome measure involved difference scores in the number of balls tossed to Player 1 between two conditions of the task. Across both conditions, the participant (always assigned as "Player 2") played with 3 other on-line players in real time. In Condition 1, Player 1 was programmed to toss on average 70% of his balls to the participant. In Condition 2, Player 1's behavior switched such that he was programmed to toss on average only 10% of his balls to the participant. The data reported below is the number of balls tossed to Player 1 in Condition 2 minus balls tossed under Condition 1.

Disengagement From Social Threat CuesDay 1 (first day oxytocin or placebo was administered)

The outcome measure involved difference scores in response latencies on disengagement trials for disgust versus neutral cues. Difference scores were calculated as response latencies during disengagement trials for disgust cues minus response latencies during disengagement trials for neutral cues. Negative change scores represent an improvement in disengagement.

Secondary Outcome Measures
NameTimeMethod
Perceived Trust Scores on a 1-7 Likert ScaleDay 1 (first day oxytocin or placebo was administered)

Participants will rate their perceived level of trust (on a 1-7 Likert scale) toward Player 1 during online ball-tossing task. Higher ratings on this scale reflect greater perceived trust toward Player 1.

Perceived Empathy Scores on a 1-7 Likert ScaleDay 1 (first day oxytocin or placebo was administered)

Participants will rate their level of perceived empathy (on a 1-7 Likert scale) with Player 1 during online ball-tossing task. Higher scores on this scale reflect greater perceived empathy toward Player 1.

Perceived Preference Scores on a 1-7 Likert ScaleDay 1 (first day oxytocin or placebo was administered)

Participants will rate their level of preference (on a 1-7 Likert scale) for Player 1 during online ball-tossing task. Higher scores on this scale reflect greater preference for Player 1.

Perceived Rejection Scores on a 1-7 Likert ScaleDay 1 (first day oxytocin or placebo was administered)

Participants will rate their level of perceived rejection (on a 1-7 Likert scale) from Player 1 during online ball-tossing task. Higher scores on this scale reflect greater perceived rejection from Player 1.

Trial Locations

Locations (1)

Center for Anxiety and Related Disorders at Boston University

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath